MiNK Therapeutics, Inc. INKT
10.22 USD +0.21 (+2.14%)
At closeNov 11, 2026, 6:03 PM EST
10.22 0.00 -0.04%
After hours · Nov 11, 6:03 PM ET
10.02 Day range 10.88
8.48 52-week range 16.93
- YTD
- -8.31%
- 1 year
- -25.15%
News
seekingalpha.com MiNK Therapeutics, Inc. (INKT) Q3 2026 Earnings Call Transcript MiNK Therapeutics, Inc. (INKT) Q3 2026 Earnings Call Transcript
zacks.com MiNK Therapeutics, Inc. (INKT) Reports Q3 Loss, Beats Revenue Estimates MiNK Therapeutics, Inc. (INKT) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.65 per share a year ago.
marketbeat.com What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call MiNK Therapeutics NASDAQ: INKT has initiated a randomized Phase 2 trial of its investigational cell therapy agenT-797 in patients with severe acute lung injury and respiratory distress, with…
benzinga.com MiNK Therapeutics Q3 2026 Earnings Call Transcript MiNK Therapeutics (NASDAQ:INKT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com MiNK Therapeutics Q3 EPS $(0.50) Beats $(0.66) Estimate MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.66) by 24.24 percent. This is a 23.08 percent increase over losses of…- benzinga.com MiNK Therapeutics Presents Preclinical Cancer Data For iNKT Cell Therapy Platform At SITC 2026 Colorectal cancer: in a human liver-metastasis organoid model resistant to botensilimab and balstilimab alone, the addition of agenT-797 supported immune reprogramming and tumor-cell killing,…
globenewswire.com MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026) NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies,…
benzinga.com HC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38 HC Wainwright & Co. analyst Matthew Keller assumes MiNK Therapeutics (NASDAQ:INKT) with a Buy rating and announces Price Target of $38.
benzinga.com MiNK Therapeutics To Hold Webcast On Nov. 11 To Review Financial Results, Offer Update On Its Clinical Development Of AgenT-797 MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today…
benzinga.com B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50 B. Riley Securities analyst Mayank Mamtani reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and raises the price target from $43 to $50.
benzinga.com MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For…- benzinga.com MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 41.51 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Earnings Scheduled For May 15, 2026 - benzinga.com Earnings Scheduled For March 31, 2026
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Domo Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket Domo Inc (DOMO) stock jumped 48.8% in pre-market trading after beating Q4 earnings expectations by 117.65% and reporting a rise in revenue.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - benzinga.com Earnings Scheduled For November 14, 2025
- benzinga.com Earnings Scheduled For August 14, 2025
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket 
benzinga.com Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why Datavault AI Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Earnings Scheduled For May 15, 2025
- benzinga.com Earnings Scheduled For March 18, 2025
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For November 14, 2024
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.
benzinga.com Earnings Scheduled For March 21, 2024 Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.- benzinga.com Earnings Scheduled For November 9, 2023 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session